Status:

COMPLETED

Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development

Lead Sponsor:

University Hospital, Lille

Collaborating Sponsors:

Innovative Medicines Initiative

Conditions:

Alzheimer Disease

Battery

Eligibility:

MALE

18-30 years

Phase:

PHASE1

Brief Summary

The early assessment of new drugs for Alzheimer's disease remains difficult because of the lack of predictive end-point. The use of a battery including different parameters could improve this early de...

Detailed Description

The aim of the present study is to test the effect of a 15-day treatment with donepezil on a mixed battery associating cognitive assessment, imaging and neurophysiological tests in healthy volunteers....

Eligibility Criteria

Inclusion

  • 18-30 year old male non-smoker subjects
  • Subject without cognitive impairment or cognitive complaint (Moca\>26, Mac Nair scale\<15)
  • Subject without history of brain disease (severe brain trauma, stroke, cerebral tumor,…)
  • Subject without major medical or surgical history
  • Subject without current chronic disease
  • Subject without current cerebral disease
  • Subject without vascular or metabolic risk factor
  • Subject without history or current mental disease or addiction (MINI)
  • Subject without lesion on MRI
  • Subject without abnormal electrical activities on EEG
  • Subject without use of chronic treatment or psychotropic drugs or substances
  • French speaker subject and able to understand the test instructions

Exclusion

  • Subject with age \< 18 years or \> 30 years
  • Subject with dementia or cognitive decline identified by Moca \< 26
  • Subject with history of brain disease (brain trauma, stroke, cerebral tumor,…)
  • Subject with major medical or surgical history
  • Subject with current chronic disease
  • Subject with current cerebral disease
  • Subject with vascular or metabolic risk factor
  • Subject with history or current mental disease or addiction
  • Subject with family history of young-onset dementia
  • Subject with family history of chronic or severe neurological or mental disease (first degree relatives)
  • Subject with lesion on MRI
  • Subject with abnormal electrical activities on EEG
  • Subject receiving a chronic treatment
  • Subject using chronically or acutely psychotropic drugs or substances
  • Subject with claustrophobia or contra-indication to MRI
  • Subject unable to understand the test instructions

Key Trial Info

Start Date :

December 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2013

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT01487395

Start Date

December 1 2011

End Date

December 1 2013

Last Update

April 9 2015

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

CHRU de Lille/ Centre d'investigation Clinique

Lille, France, 59037

2

CIC Marseille

Marseille, France

3

CIC Toulouse

Toulouse, France